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Abstract
Introduction: Thrombocytosis is a common disorder in patients diagnosed with iron deficiency anemia. The decreased platelet 
counts commonly found iron deficiency anemia is rarely reported in clinical practice. The exact mechanism of the occurrence of 
thrombocytopenia in iron deficiency anemia remains unclear. In this case report we discuss a triad of symptoms seen in the African 
American population: Iron deficiency anemia, menorrhagia and thrombocytopenia.
Case presentation: A 40 year old multiparous African-American woman presented with heavy vaginal bleed, severe anemia (3.5 g/dL) 
and thrombocytopenia (30,000/mm3). The peripheral blood smear showed marked microcytic hypochromic cells with decreased platelets 
counts. After excluding other causes of thrombocytopenia and anemia, increased red cell distribution width and low iron saturation 
  confirmed the diagnosis of iron deficiency anemia. Treatment for iron deficiency anemia was initiated with intravenous and oral iron 
supplements. Two months following treatment of iron deficiency anemia, the triad of manifestations resolved and patient remained 
stable.
Conclusion: Profound degree of iron deficiency anemia can present with thrombocytopenia and severe menorrhagia. Iron replacement 
should be the main treatment goal in these patients. This case report further supports the 2 compartment model of the role of iron in 
maintaining platelet counts.
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Introduction
Iron deficiency anemia is the second most common 
nutritional deficiency in the United States with an 
estimated 3.3 million females in their reproductive 
life affected by iron deficiency.1 Almost all patients 
with iron deficiency will have normal or elevated 
platelet  counts,  some  higher  than  1000  ×  109/L 
at  diagnosis,  however,  thrombocytopenia  in 
association with iron deficiency is rarely reported.2,3 
The exact mechanism of thrombocytopenia is not 
well  understood  and  is  postulated  to  have  a  role 
in  alteration  in  the  activity  of  iron-dependent 
enzymes in megakaryocytes and thrombopoiesis.4 
In  1978,  Beard  and  colleague5  first  noticed  the 
triad  of  combination  of  iron  deficiency  anemia, 
thrombocytopenia  and  heavy  vaginal  bleeding  in 
alpha-1 thalassemia trait patients. Later on, Berger 
and colleagues6 noticed a similar triad of symptoms 
without  any  hemoglobinopathy.  Since  then,  very 
few  cases  have  reported  this  triad.  The  purpose 
of this case report is to explore the triad further 
for  the  combination  of  iron  deficiency  anemia, 
heavy  vaginal  bleeding  and  thrombocytopenia 
and  to  define  whether  iron  supplements  is  an 
effective approach to treat all three manifestations   
together.
Case Summary
A  40  year-old  African  American  woman  was 
  admitted to the intensive care unit for heavy   vaginal 
  bleeding  that  lasted  4  days.  Vaginal  bleeding 
was    associated  with  lightheadedness,  palpitation, 
  weakness  and  fatigue.  She  reported  a  seven  year 
history of   uterine leomyomas that caused recurrent 
episodes  of  menorrhagia.  Due  to  inadequate  iron 
supplemention,  she  consequently  developed  iron   
deficiency.
Physical  examination  revealed  a  blood  pressure 
110/70 mmHg, a heart rate of 105 bpm, a respira-
tory  rate  of  18  breaths/min,  and  a  temperature  of 
98 degrees   Fahrenheit. She appeared pale; no icterus, 
petechiae,  ecchymosis,  or  purpuric  lesions  noted. 
She had no   lymphadenopathy. Lungs were clear to 
auscultation.    Cardiac  examination  revealed  cardiac 
grade  2/6  to  3/6  s  ystolic  flow  murmur.  The  liver 
span was 9 cm and spleen was not palpable. Pelvic 
  examination showed vaginal bleeding. No bleeding 
from any other site was observed.
Initial laboratory data is summarized in Table 1. 
Her  Hemoglobin  level  was  3.5  g/dL  (normal 
range;  12.1–15.1  g/dL)  and  platelet  count  was 
30,000/mm3  (normal  range:  150–400  ×  109  per 
liter).  Mean  corpuscular  volume  (MCV)  was  56.6 
femtolitre  (normal  range;  80–100  femtolitre)  and 
Red  cell  distribution  width  (RDW)  was  37.6; 
(normal  range;  11%–15%).  Reticulocyte  count  on 
admission  was  1.3%  (normal  range;  0.5%–1.5%). 
Iron studies revealed serum iron 27 µg/dL (normal 
range;  50–170  µg/dL)  serum  ferritin  7.79  ng/dL 
(normal range; 12–150 ng/mL), serum transferring 
419.9 mg/dL (normal range 204–360 mg/dL), percent 
saturation was 4%. Results of the iron studies were 
consistent with iron deficiency anemia. The peripheral 
blood smear showed marked microcytic hypochromic 
cells with decreased numbers of platelets. No platelet 
clumping was noticed (Figure 1A and B).
Her coagulation parameters were normal. Work up 
for systemic lupus erythematosus, HIV, immune and 
non-immune mediated thrombocytopenia, thrombotic 
thrombocytopenic  purpura  was  unremarkable. 
  Ultrasound  of  pelvis  showed  an  anteverted  uterus 
with heterogenous parenchyma and calcified anterior 
myoma and 0.44 cm ecchodense wall thickness with 
adenomyosis.
The patient was administered four units of packed 
red blood cells, two doses of intravenous iron sucrose 
complex 125 mg for two consecutive days, oral iron 
sulphate tablets 325 mg three time a day, vitamin C 
500 mg orally daily and Northindorne 10 mg orally 
three times a day.
On  day  5,  she  was  discharged  home  with 
hemoglobin of 10.3 and platelet count 79,000/mm3. 
Upon discharge the patient was advised to take oral 
iron  supplements  and  proceed  with  hysterectomy. 
Sixty  days  after  iron  supplementation  and 
post-hysterectomy,  platelet  count  improved  to 
4,47000/mm3, hemoglobin increased to 10.9 g/dL and 
reticulocyte count 2.8% (normal range; 0.5%–1.5%). 
Figure  2A  and  B  describes  the  platelets 
counts and hemoglobin trend after inititating iron 
therapy.
The  resolution  of  severe  symptomatic  anemia 
along with thrombocytopenia following iron supple-
mentation strengthens the hypothesis that iron therapy 
plays an important role in improving iron deficiency 
anemia associated thrombocytopenia.Iron deficiency anemia, thromobocytopenia and menorrhagia
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Discussion
Iron  deficiency  anemia  has  been  known  to  be 
associated  with  reactive  thrombocytosis.2–4  In 
this  report  we  discussed  the  rare  ocurrence  of 
menorrhagia, thrombocytopenia and iron deficiency 
anemia that is rarely reported in the literature.5,6 This 
report further illustrates that iron deficiency anemia 
treatment  with  iron  supplements  can  correct  the 
associated decrease in platelet counts. The resolution 
of thrombocytopenia with iron supplementation will 
occur  provided  other  causes  of  thrombocytopenic 
disorders  are  excluded  such  as  acute  hemorrhage, 
hemolysis, chronic inflammatory disorders, trauma, 
folate  deficiency  and  Vitamin  B12  deficiency  and 
thrombotic thrombocytopenic purpura.
Polette et al8 have demonstrated in animal models 
that iron, a key element in lipid peroxidation, plays an 
important role in platelet aggregation. Iron produces oxy-
gen free radicals that induce the release of arachidonic 
acid and thromboxane A 2 from platelet   phospholipids. 
Barradas et al9 demonstrated that iron chelators such as 
deferoxamine  inhibited  platelet  aggregation,  produc-
Table 1. Laboratory results on admission to hospital and two month after presentation.
Laboratory On admission Value after 60 days Reference value
Leukocyte count 6.4–10 × 3/mm3 6.3 –10 × 3/mm3 4.5–10 × 3/mm3
Hemoglobin 3.5 g/dL 10.9 g/dL 12.0–15.2 g/dL
Hematocrit 11.2% 33.3% 37%–46%
platelet count 43.10 × 3/mm3 447.10 × 3/mm3 140–450 × 3/mm3
MCV 56.6 µm3 78 µm3 78–101 µm3
Reticulocyte count 1.3% 2.8% 0.5%–1.5%
Serum iron 27 µg/dL N/A 26–170 µg/dL
Serum ferritin 7.79 ng/Ml N/A 12–160 ng/Ml
Serum transferrin 419.90 mg/dL N/A 204–360 mg/dL
Serum vitamin B12 795 pg/mL N/A .150–200 pg/mL
Serum folate .20 ng/mL N/A 2.7–17 ng/mL
Haptoglobin 142 mg/dL N/A 41–165 mg/dL
Blood glucose 98 mg/dL N/A 65–110 mg/dL
BUN 12 mg/dL N/A 7–21 mg/dL
Creatinine 0.9 mg/dL N/A 0.5–1.4 mg/dL
AST 13 U/L N/A 5–35 U/L
ALT 14 U/L N/A 7–56 U/L
Total protein 6.1 g/dL N/A 15–45 g/dL
Total bilirubin 0.9 mg/dL N/A 0.2–1.3 mg/dL
LDH 419 U/L N/A 105–333 U/L
pT 11 12 11–13.5 seconds
INR 1.1 1.2 0.8–1.2
pTT 23 25 25–35 seconds
Figure 1 (A) [200X] and (B) [400X] peripheral blood smear showed marked microcytic hypochromic cells with decreased numbers of platelets.Ibrahim et al
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tion of thromboxane and lipoxygenase activity suggest-
ing platelet aggregation is dependent on iron.
In patients with menorrhagia, inadequate contraction 
of spiral arterioles in the endometrium leads to qualitative 
and quantitative platelet dysfunction causing prolonged 
period of heavy menstrual flow.10 In order to understand 
possible interactions between iron deficiency anemia, 
platelet behavior and menorrhagia, Akoy et al11 evaluated 
the effect of iron therapy on platelet function among 
women with menorrhagia. They found iron deficiency 
anemia  in  women  caused  arachidonic  acid  induced 
platelet  dysfunction  through  iron-containing  enzymes 
may give rise to increased menstrual blood loss, which 
can  be  reversed  through  iron  repletion.  Kiem  et  al12 
showed that iron is present in platelets in a concentration 
of  approximately  12.28  µg/g,  further  supporting  the 
hypothesis of Karpatkin and colleagues13 that iron may 
have a functional role in controlling platelet production.
A 2-compartment model has been designed to study 
the role of iron in maintenance of platelet counts and 
reactive thrombocytosis.14 The two main components 
include the “inhibitor” compartment and the “essential 
component.” In the “inhibitor” compartment, iron either 
directly or indirectly inhibits the rise in platelet count 
above steady state levels via an unknown mechanism. 
This postulated mechanism accounts for thrombocytosis 
that occurs following iron depletion through blood loss 
or an iron-deficient diet. In the “essential component” 
compartment  of  the  model,  iron  is  required  in  the 
synthesis  or  production  of  platelets.  During  iron 
depletion, thrombopoiesis will begin until sufficient iron 
is available in the “essential” compartment for synthesis 
of platelets. This supports the two compartment model 
of iron’s role in maintaining platelet counts.14
In  our  case,  patient  had  severe  iron  deficiency, 
as  manifested  by  hemoglobin  level  of  3.5  g/dL  and 
thrombocytopenia 30,000/mm3. Therefore, at the time of 
initial presentation, iron stores of the essential component 
compartment  were  exhausted  and  thrombocytopenia 
ensued. When iron was replaced in the form of packed 
erythrocyte  transfusions  and  iron  supplementation, 
thrombopoiesis occurred and the platelet count returned 
to normal. Finally, she progressed to thrombocytosis 
owing  to  secondary  overshoot  resulting  from  the 
function  of  iron  in  the  inhibitor  compartment.  Our 
patient did not require any platelet transfusion.
An  increasing  reticulocyte  count  is  a  reliable 
way  to  confirm  iron  responsiveness  during  the 
initial period of observation and supplementation. In 
patients with concomitant thrombocytopenia, a rapid 
rise in the platelet count also can serve as evidence 
of  an  appropriate  hematological  response  to  iron 
replenishment. Similar to our case, Ganti et al15 had 
a case of a 39 year female Jehovah’s Witness with a 
10  month  history  of  menorrhagia  and  pancytopenia 
and  severe  iron  deficiency.  Since  blood  transfusion 
was not allowed, she was started on intravenous iron 
replacement therapy which caused initial leucopenia and 
thrombocytopenia  which  recovered  upon  continuing 
iron supplementation Again such finding in similar cases 
clarifies the potential role of iron in thrombocytopenia 
associated with iron deficiency anemia.
Conclusion
Iron supplements can improve iron deficiency anemia, 
platelet  counts  and  menorrhagia.  This  case  further 
supports the two compartment iron’s role in maintenance 
of platelet counts. Physicians should be aware of unex-
plained menorrhagia with normal coagulation profile. 
500
450
400
350
300
250
200
150
100
50
0
0 20
Time (in days)
40 60
Platelet count
Platelets
Figure 2A. Response to iron therapy plotted against time. 
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Figure 2B. Hemoglobin level after iron supplementation.Iron deficiency anemia, thromobocytopenia and menorrhagia
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Patients can present with severe iron deficiency ane-
mia and thrombocytopenia. It is highly desirable that 
life threatening conditions like thrombotic thrombocy-
topenic purpura and other causes of thrombocytopenia 
should be excluded. Future studies should focus more 
on the hemoglobin and iron levels cut off to determine 
which subset of patient’s population can present with 
thrombocytopenia.
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